BioWorld Asia

Jan. 26, 2005

OctoPlus Raises EUR18.25M For Drug Development, Delivery

OctoPlus BV raised €18.25 million (US$23.6 million) in a second funding round that will enable it to progress its drug development and delivery programs and to widen its product pipeline. (BioWorld International) Read More

CeNeS Gets Positive Phase III Data For M6G, Plans Another

Immune Cells Reprogrammed As Cancer Killers, Study Shows

Stroke Company Paion AG Testing German IPO Waters

Crucell Mulls Funding Moves For Clinical Studies In 2005

UroGene Sells Research Center, Cancer Programs to Pierre Fabre

With More Phase III Data, GW Hoping For IND Filing In U.S.

Other News To Note

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 17, 2026

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...